INTRODUCTION
The national incidence of esophageal cancer has risen steadily and has increased 7-fold since the 1970s.
1, 2 In 2016, there will be an estimated 16,900 newly diagnosed cases; roughly 50% to 60% of these patients will present with potentially resectable disease. 2, 3 Although esophagectomy has traditionally been the mainstay of curative treatment, prior studies have suggested that it is severely underused. [4] [5] [6] Possible explanations include a nihilistic attitude toward surgery because of historically high postoperative morbidity and mortality, variations in access to treatment, and a paucity of definitive evidence to guide therapy. 5, 6 However, recent paradigm shifts in the management of potentially curable disease call for a reevaluation of surgical utilization.
The development of new treatment modalities and advances in operative technique have changed the therapeutic landscape. National Comprehensive Cancer Network guidelines first recommended endoscopic local therapy as a primary option for early-stage disease in 2008 and as a preferred treatment in 2012. However, esophagectomy persists as an accepted alternative for stage 0 and I disease and continues to be integral to the management of stage II and III disease. 7 Furthermore, improved outcomes with minimally invasive approaches may allow patients who were previously considered too high-risk for resection to benefit from surgical treatment. [8] [9] [10] The optimal management of locoregional disease continues to evolve. National guidelines promote preoperative chemoradiation followed by esophagectomy but allow for multiple therapeutic pathways. 7 Although the necessity of surgical treatment for squamous cell tumors has been challenged, 6, 11 National Comprehensive Cancer Network recommendations support definitive chemoradiation only for patients who refuse surgery, are medically unfit for resection, or present
The impact of conflicting treatment strategies, expanded therapeutic options, and improved surgical outcomes on practice patterns remains unknown. We sought to evaluate national utilization of esophagectomy and local therapies over time and to identify factors associated with surgical treatment for patients with local or locoregional esophageal cancer.
MATERIALS AND METHODS
We conducted a retrospective cohort study with the National Cancer Data Base (NCDB), a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society. The NCDB collects data from more than 1500 Commission on Cancer-accredited facilities nationwide. The database captures more than 70% of newly diagnosed cancer cases in the United States and Puerto Rico each year. Because the NCDB is a deidentified, readily available data set, this study was not subject to institutional review board approval.
Study Population
We selected patients who were 18 years old or older and had been diagnosed with adenocarcinoma or squamous cell carcinoma of the esophagus or gastroesophageal junction from 2004 to 2013. The NCDB records data from a single reporting facility; we excluded patients who were diagnosed at the reporting facility but received all treatment elsewhere. The clinical stage was reported according to the American Joint Committee on Cancer staging edition at the time of diagnosis, and we collapsed this variable (eg, stages IA and IB were categorized as stage I). We excluded patients with documented clinical evidence of metastatic disease or tumors of the cervical esophagus, which were identified according to the 3rd edition of International Classification of Diseases for Oncology (C15.0; Fig. 1 ). 13 The median household income was based on the patient's home zip code at the time of diagnosis. We considered community and comprehensive community treatment centers together; we called them community hospitals.
Treatment Definitions
The NCDB reports therapies administered as part of the planned initial course of treatment, and given the disease stages selected for analysis, we presumed that patients underwent surgery with a curative intent. Potentially curative surgical treatment includes esophagectomy (codes 30-80) and endoscopic local therapy (codes 10-27 and 90) according to Facility Oncology Registry Standards.
14 A detailed distribution of local therapies is provided in Table 1. The NCDB defines these interventions as "surgery" and reports the reason for no surgical treatment according to the categories depicted in Figure 1 . "Surgery not part of the first course of treatment" includes situations in which patients were given multiple options and chose medical therapy or did not receive any treatment.
Analysis
The primary outcome was the rate of potentially curative surgical treatment from 2004 to 2013. We used logistic regression with the year of diagnosis as a continuous predictor to evaluate treatment rates over time. The comparison of patient and facility characteristics was performed with Pearson chi-square tests for categorical variables. To evaluate predictors of surgical treatment, we performed a multivariate analysis using a binary logistic regression model with the year of diagnosis as the main predictor, and we included age, sex, race, Charlson-Deyo comorbidity score, insurance status, median household income, American Joint Committee on Cancer clinical stage, histology, facility type, and geographic region as a priori defined covariates. We performed a sensitivity analysis excluding patients who died before surgery or for whom surgery was not recommended because of patient risk factors.
We performed 2 subgroup analyses. First, because local therapy is preferred over esophagectomy for superficial lesions, we used multivariate models to identify factors associated with the receipt of esophagectomy for the subset of patients with clinical stage 0 (carcinoma in situ) or I disease who underwent potentially curative surgical treatment. Second, because the guidance on the use of definitive chemoradiation as a potentially curative alternative to esophagectomy for locoregional disease has evolved, we compared stage II/III patients who underwent esophagectomy with those who were offered multiple treatment options but opted for chemoradiation without surgery. Patients for whom surgery was contraindicated because of risk factors or who died before surgery were excluded. The significance level (a) was set at .05 for all analyses, and P values were calculated as 2-tailed. Analyses were performed with SPSS 23 (SPSS, Chicago, Ill). were predominantly white males. More than 70% presented with clinical stage II or III disease, and 64.5% had adenocarcinoma. Although approximately 13% of the hospitals in the database were academic facilities, nearly half of the study population (46.8%) was managed at these institutions (Table 2) .
RESULTS

The
Overall, 19,050 patients (36.5%) underwent esophagectomy, and 4110 (7.9%) received endoscopic local therapy. The rate of esophagectomy steadily increased from 30.7% to 37.9% (P < .001), and the use of local therapies rose from 5.6% to 9.5% (P < .001), so the overall rate of potentially curative surgical treatment increased from 36.4% in 2004 to 47.4% in 2013 (P < .001). Reasons why the remaining 28,962 patients (55.6%) did not undergo surgical treatment included death before planned surgery (n 5 275), a contraindication due to patient risk factors (n 5 3173), patient refusal (n 5 1039), and unknown reasons (n 5 2252; Fig. 1 ). Among the 22,223 patients for whom surgery was not part of the planned first course of treatment, 3761 received single-modality medical therapy with either chemotherapy or radiation, 14,408 received combined chemoradiation, and 3566 opted for no treatment.
Utilization of Surgical Treatment by Clinical Stage
For stage 0, esophagectomy use decreased from 23.8% to 17.9% (P < .001) with a concomitant rise in rates of Original Article endoscopic local therapy from 34.3% to 58.8% (P < .001). The impact of local therapies drove growth in the overall use of surgical treatment from 58.0% in 2004 to 76.7% by 2013 ( Fig. 2A) . The receipt of esophagectomy for stage I increased modestly from 29.8% to 34.5% (P 5 .16). The use of local therapies doubled from 13.6% to 27.4% (P < .001), and this contributed to an expansion of surgical treatment from 43.4% to 61.8% by 2013 for stage I (Fig. 2B ). For locoregional disease, rates of surgical treatment increased from 36.1% to 45.0% (P < .001) and from 30.8% to 38.6% (P < .001) for clinical stages II and III, respectively. The use of local therapy remained less than 2.6% (Fig. 2C,D) .
Predictors of Potentially Curative Surgical Treatment
Patients receiving surgical treatment tended to be younger, white, privately insured males with a higher median household income (P < .001). Those managed at academic centers were significantly more likely to undergo potentially curative surgical treatment than those managed at community hospitals (odds ratio , and patients with adenocarcinoma were more than 2-fold more likely to undergo surgical treatment than patients with squamous cell carcinoma (OR, 2.68; 95% CI, 2.56-2.81). In the adjusted analysis, the year of diagnosis remained a small but significant predictor (OR per year, 1.04; 95% CI, 1.03-1.04; P < .001; Table 3 ). A sensitivity analysis excluding patients who died before surgery or for whom surgery was contraindicated yielded similar findings.
Use of Esophagectomy: Clinical Stage 0 or I
For the subset of stage 0/I patients who underwent surgical treatment (n 5 7965), the adjusted analysis revealed that the receipt of esophagectomy rather than endoscopic local therapy was more likely for patients with clinical stage I disease (OR, 3.52; 95% CI, 3.08-4.02) and for those with adenocarcinoma versus squamous cell carcinoma (OR, 1.28; 95% CI, 1.06-1.37). Notably, patients managed at community facilities had significantly greater odds of being treated with esophagectomy (OR, 1.78; 4 and a subsequent analysis including in situ, local, and regional disease from 1988 to 2004 found that 44% of patients received an esophagectomy. Notably, esophagectomy rates failed to increase during the 17-year period. 5 Although exposing critical underuse, these studies were limited by small sample sizes and were conducted before the formal incorporation of local therapies into national guidelines. We noted a significant overall increase in the rates of esophagectomy driven by the clear majority of patients who presented with stage II/III disease. Although esophagectomy has been historically viewed as an invasive, highrisk procedure with questionable benefit because of low overall disease survival, 4 these findings suggest increasing acceptance of radical resection. Potential explanations for this shift include the adoption of minimally invasive esophagectomy, 8, 10 lower postoperative mortality at specialized high-volume centers, [16] [17] [18] and growing evidence from prospective studies such as the CROSS trial 19 demonstrating improved long-term survival with preoperative chemoradiation. 20, 21 In concordance with preferred treatment algorithms, endoscopic modalities were the primary contributor to increasing rates of surgical treatment for superficial cancers, and a subgroup analysis of stage 0/I disease indicates a shift away from esophagectomy. Our findings build on work by Berry et al, 22 who reported increasing use of endoscopic local therapies for T1N0 disease from 8.1% in 1998 to 24.1% in 2008. Although retrospective analyses suggest that local treatments provide effective therapy, 22, 23 because of the apparent widespread adoption of these modalities, prospective trials may be increasingly valuable for evaluating long-term outcomes. 
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We found that 61.9% of newly diagnosed cases presented with tumors considered resectable according to the clinical stage (0-III); this is consistent with previous population-based reports. 2 Although our data suggest an increase in overall surgical use, more than half of these patients received exclusively nonsurgical therapies or did not undergo treatment, and this indicated significant ongoing underutilization of potentially curative surgical options. Previous investigations have cited racial and socioeconomic disparities as drivers of surgical underuse, 4, 5 and unfortunately, we have found that this trend persists. Interestingly, although patient-level disparities were less pronounced in predictors of esophagectomy versus local therapies for stages 0 and I, we noted significant racial and socioeconomic influence in the use of esophagectomy versus definitive chemoradiation in the stage II/III subgroup. The precise etiology of this patient-level variation is uncertain but may include the following: access to care, cost of therapy, knowledge deficits related to available and preferred treatment options, and patient preference to avoid potentially onerous radical surgical resection. Further clarification of patient-related barriers to surgical treatment is needed, particularly for those with more advanced disease. Our analysis uncovered significant variations in adherence to national guidelines because academic and community hospitals demonstrated distinctly different practice patterns. We found that patients treated at community hospitals were less likely to receive surgical treatment than their counterparts at academic centers. Diverging practices persisted in both subgroup analyses: those managed at community centers were more likely to undergo esophagectomy for stage 0/I disease and were less likely to undergo esophagectomy for stage II/III tumors. Heightened deviation from preferred algorithms at nonacademic centers may stem from limited access to skilled providers who can perform local therapies or advanced minimally invasive techniques and from insufficient resources to facilitate higher level multidisciplinary postesophagectomy management of these complex patients. Because academic centers are not located in many communities, longer travel times and a hesitancy to refer patients to out-of-network providers may pose critical barriers to preferred surgical treatment, particularly in light of identified socioeconomic disparities. This facility variability highlights an opportunity to improve the awareness of current guidelines and the dissemination of local therapy options at the community level.
Ongoing controversy exists regarding the optimal management of patients with squamous cell carcinomas. Although a recent Cochrane review found no difference in long-term mortality or recurrence for patients treated with definitive chemoradiation versus surgery, the quality of evidence was low or very low. 24 Our results demonstrate that patients with squamous cell carcinoma were almost 3 times less likely to have surgical therapy than those with adenocarcinoma. This histology-based deviation provides evidence to support the impact of European guidelines 12 endorsing definitive chemoradiation on practice patterns in the United States.
It is worth noting that for the majority of patients who did not undergo surgical therapy, the reason was documented as "surgery not part of the first course of treatment." This includes a heterogeneous group of patients; it is unknown how many were offered surgery and chose alternative therapy versus how many were not offered surgery. However, this category is distinct from those for whom surgery is contraindicated, and thus we presume that it represents patients who are potentially surgical candidates. Further characterization of patients who do not undergo curative treatment offers tremendous potential to increase utilization, address potential surgeon bias, and improve patients' understanding of therapeutic options.
Our use of the NCDB offers an analysis of a significantly larger nationally representative sample in comparison with previous reports. However, this study has several limitations. We included all patients with potentially resectable disease according to the clinical stage to facilitate comparisons with earlier studies. Although our cohort contained patients for whom surgery was contraindicated or who died before treatment, these patients represented a small proportion, and a sensitivity analysis produced similar results. Because of changes in American Joint Committee on Cancer staging guidelines during the study period, our cohort included 725 patients (1.4% of the total cohort) with T4b lesions for whom definitive chemoradiation is currently recommended. We believe that the inclusion of these patients was justified to facilitate comparisons with earlier studies because before 2010 the distinction between T4a and T4b lesions did not exist. The NCDB does not provide information on how patients were staged, so we were unable to assess the quality and accuracy of staging information, and although it offers some data on patient characteristics, this database lacks the granularity necessary to better define differences between those for whom surgical therapies were and were not recommended. Unfortunately, the database records information only for a single reporting facility, and thus we acknowledge that our analyses do not account for patients who were diagnosed at the reporting hospital but received all treatment elsewhere. However, this scenario occurred for less than 4% of the patients in the database with clinical stage 0 to IV disease, and because of the otherwise large sample size, the exclusion of these patients was unlikely to have had a substantial impact on the overall trends. Finally, these data represent the planned initial treatment strategy; the NCDB does not report subsequent therapies after failed first-course treatments. Therefore, it is likely that overall utilization of surgical treatment is greater than these results indicate because there are certainly patients who underwent esophagectomy after failed local therapy, salvage resection after definitive chemoradiation, or subsequent local therapy such as cryotherapy with palliative intent.
In conclusion, using a large national sample, we have demonstrated increased use of surgical treatment from 2004 to 2013 for stage 0 to III esophageal cancer. The impact of local therapies has significantly expanded the receipt of surgical treatment for superficial tumors.
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